《新股消息》360數科(QFIN.US)通過聆訊 將來港作第二上市
內地信貸科技平台360數科(QFIN.US)近日通過聯交所聆訊,將來港作第二上市,保薦人為花旗和中金。
聆訊後招股資料顯示,公司主要收入來源是向金融機構提供技術解決方案所得的服務費,截至今年6月底已與133家金融機構建立合作夥伴關係,累計為2,560萬名借款人撮合貸款共近1.13萬億元人民幣。
今年首三季,公司淨收入總額達到126.47億元人民幣,按年升3.55%。淨利潤則下跌29.3%至31.5億元。公司表示,來港上市集資預料將用於增強技術及信用評估能力、滲透信貸科技行業及擴大用戶群體,以及一般營運用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.